LISBON - Vaxxinity, Inc. (NASDAQ:VAXX), a biotechnology firm based in the United States, has reported a significant development in the potential treatment of Parkinson's disease. At the AD/PD™ 2024 International Conference on Alzheimer's and Parkinson's Disease, the company presented positive clinical data from its UB-312 program.
UB-312 is an active immunotherapy candidate that has shown to reduce pathological alpha-synuclein (aSyn) in the cerebrospinal fluid (CSF) of patients with Parkinson's, which is a first in the field. The treatment targets aggregated forms of aSyn, which are considered toxic and a key factor in the development of Parkinson's and other synucleinopathies.
The Phase 1 clinical trial, which was randomized, double-blind, and placebo-controlled, included a collaborative project funded by The Michael J. Fox Foundation. This project involved Vaxxinity, the Mayo Clinic, and UTHealth Houston analyzing CSF from patients and conducting research to assess target engagement.
Patients treated with UB-312 exhibited a 20% decrease in aggregated aSyn in the CSF, in contrast to a 3% increase in the placebo group. This result was measured by a Seed Amplification Assay (SAA) and was statistically significant.
Additionally, a post hoc analysis revealed that patients with detectable UB-312-induced antibodies in the CSF showed improvement in daily living activities, according to the MDS-UPDRS II clinical scale.
Lou Reese, Co-Founder and Executive Chairman of Vaxxinity, expressed optimism about the potential of UB-312 to change the conversation around Parkinson's treatment and prevention. The company anticipates publishing these results in a peer-reviewed scientific journal shortly.
The trial's findings from healthy volunteers in Part A were published in 2022, indicating that UB-312 is generally well-tolerated and immunogenic. Vaxxinity is dedicated to developing disease-modifying active immunotherapies for various chronic diseases, including Alzheimer's disease, migraine, and hypercholesterolemia, in addition to Parkinson's disease.
This information is based on a press release statement from Vaxxinity, Inc.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.